Alpha Cognition Secures New U.S. Patent for ZUNVEYL Dosing Regimens

Event summary

  • Alpha Cognition received U.S. Patent No. 12,551,491 covering oral dosing regimens for benzgalantamine in treating mild to moderate Alzheimer’s disease.
  • The patent extends U.S. protection for ZUNVEYL through July 2045, reinforcing its intellectual property portfolio.
  • Michael McFadden, CEO, highlighted the patent’s role in strengthening ZUNVEYL’s long-term differentiation and commercial value.
  • ZUNVEYL is Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease.

The big picture

Alpha Cognition’s new patent bolsters its intellectual property strategy for ZUNVEYL, a critical asset in the competitive Alzheimer’s disease treatment landscape. The move aligns with broader industry trends where biopharmaceutical companies fortify their IP portfolios to secure long-term market exclusivity and commercial advantage. The patent’s extension through 2045 underscores the company’s focus on sustaining ZUNVEYL’s differentiation in a market dominated by established therapies like donepezil and rivastigmine.

What we're watching

Market Differentiation
How the new patent will affect ZUNVEYL’s competitive positioning against existing Alzheimer’s treatments.
Regulatory Protection
Whether the extended patent exclusivity will deter potential generic competition in the U.S. market.
Commercial Strategy
The pace at which Alpha Cognition can leverage this IP strength to expand ZUNVEYL’s market share.